Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Heart Failure
  Free Subscription

Articles published in
Cardiovasc Res
    March 2026
  1. ZHU C, Xue Y, Hong W, Zhu Y, et al
    Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2.
    Cardiovasc Res. 2026 Mar 20:cvag066. doi: 10.1093.
    >> Share

    February 2026
  2. PAN Q, Chen C, Zhang C, Jiang Y, et al
    Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction.
    Cardiovasc Res. 2026 Feb 5:cvag030. doi: 10.1093.
    >> Share

  3. KLEINBONGARD P, Beyer AM
    Telomer length, integrity vs. telomerase-activity - who is to blame for heart failure?
    Cardiovasc Res. 2026 Feb 3:cvag026. doi: 10.1093.
    >> Share

  4. HEGNER P, Baier MJ, Krammer T, Seitz S, et al
    Semaglutide improves contractile function in human atrial myocardium of patients with heart failure and preserved ejection fraction.
    Cardiovasc Res. 2026 Feb 3:cvag039. doi: 10.1093.
    >> Share

    January 2026
  5. KARAMPINOS KI, Farmakis D, Gurung R, Foo RS, et al
    Ferroptosis in heart failure: from molecular insights to therapeutic implications.
    Cardiovasc Res. 2026 Jan 31:cvag019. doi: 10.1093.
    >> Share

  6. NAH J, Sung EA, Zhai P, Maejima Y, et al
    Cardiomyocyte-specific deficiency of C/EBPbeta aggravates pressure overload-induced heart failure.
    Cardiovasc Res. 2026 Jan 30:cvag029. doi: 10.1093.
    >> Share

  7. BRANDT M, Khraisat S, Luo Q, Mayerle M, et al
    Integrative transcriptomic profiling links telomere dysfunction to cGAS-STING activation in heart failure signatures in mice and humans.
    Cardiovasc Res. 2026 Jan 22:cvag013. doi: 10.1093.
    >> Share

    December 2025
  8. SILVA ED, Tome I, Vasques-Novoa F, Conceicao G, et al
    Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF.
    Cardiovasc Res. 2025;121:2385-2403.
    >> Share

  9. RAMOVS V, Chen HS, Patra A, Tjokrodirijo R, et al
    KLHL24 mutation drives intermediate filament degradation, mitochondrial dysfunction and fibrosis in heart failure patients.
    Cardiovasc Res. 2025 Dec 5:cvaf231. doi: 10.1093.
    >> Share

    November 2025
  10. HE M, Tay WT, Song N, Liu T, et al
    Cardioprotective role of RBFox1 in myocardial infarction-induced heart failure.
    Cardiovasc Res. 2025 Nov 26:cvaf206. doi: 10.1093.
    >> Share

  11. ADRAH Y, Hegemann N, Faidel D, Kucherenko MM, et al
    Defining HFpEF in rodents: a systematic review.
    Cardiovasc Res. 2025;121:2134-2143.
    >> Share

  12. MATSUMOTO S, Butt JH, Docherty KF, Jhund PS, et al
    Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fraction.
    Cardiovasc Res. 2025 Nov 18:cvaf235. doi: 10.1093.
    >> Share

  13. ZEDER K, Brown CH, Santi A, Cvirn L, et al
    The prevalence of pulmonary hypertension associated with left heart disease - a systematic review and meta-analysis.
    Cardiovasc Res. 2025 Nov 11:cvaf226. doi: 10.1093.
    >> Share

  14. REDGRAVE RE, Booth LK, Richardson GD
    From immunosenescence to diastolic dysfunction: Tracing the senescence cascade in heart failure with preserved ejection fraction.
    Cardiovasc Res. 2025 Nov 8:cvaf220. doi: 10.1093.
    >> Share

    October 2025
  15. METHAWASIN M, Meinke S, Radke MH, Farman GP, et al
    Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF).
    Cardiovasc Res. 2025 Oct 17:cvaf171. doi: 10.1093.
    >> Share

  16. DAGAN M, Beale A, Wang B, Vizi D, et al
    Insights into pulmonary remodelling in heart failure with preserved ejection fraction through transpulmonary biomarker gradients.
    Cardiovasc Res. 2025 Oct 16:cvaf196. doi: 10.1093.
    >> Share

  17. OBEIDAT M, Eisner DA
    A RADical approach to treating heart failure.
    Cardiovasc Res. 2025 Oct 10:cvaf184. doi: 10.1093.
    >> Share

  18. ELMORE G, Lohano SS, McVay NM, Levitan BM, et al
    RRAD-reduction reveals efficacy of targeting L-type calcium channel regulation for treatment of heart failure.
    Cardiovasc Res. 2025 Oct 1:cvaf169. doi: 10.1093.
    >> Share

    September 2025
  19. CHUNG B, Jonas W, Rostami F, Malik Z, et al
    Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure.
    Cardiovasc Res. 2025 Sep 25:cvaf173. doi: 10.1093.
    >> Share

    August 2025
  20. HASTINGS MH, Zhou Q, Wu C, Shabani P, et al
    Cardiac ageing: from hallmarks to therapeutic opportunities.
    Cardiovasc Res. 2025;121:1474-1488.
    >> Share

    July 2025
  21. BOGDANOV V, Mariangelo JIE, Soltisz AM, Sakuta G, et al
    Distinct intracellular spatiotemporal expression of Calmodulin genes underlies functional diversity of Calmodulin-dependent signalling in cardiac myocytes.
    Cardiovasc Res. 2025;121:1052-1065.
    >> Share

    June 2025
  22. LI F, Du WW, Li X, Wen S, et al
    A new protein isoform encoded by human circular RNA circSLC8a1 contributes to cardiac remodelling.
    Cardiovasc Res. 2025;121:882-899.
    >> Share

  23. RAYNER JJ, Abdesselam I, Pan J, Lewis AJM, et al
    Obesity and heart failure: exploring the cardiometabolic axis.
    Cardiovasc Res. 2025 Jun 3:cvaf090. doi: 10.1093.
    >> Share

    May 2025
  24. CELIK S, Hyrefelt L, Czuba T, Li Y, et al
    Antisense-mediated regulation of exon usage in the elastic spring region of Titin modulates sarcomere function.
    Cardiovasc Res. 2025;121:629-642.
    >> Share

    April 2025
  25. MIRA HERNANDEZ J, Shen EY, Ko CY, Hourani Z, et al
    Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic heart failure with preserved ejection fraction model.
    Cardiovasc Res. 2025;121:254-266.
    >> Share

  26. WONG LL, Koh HWL, Choi H, Zou R, et al
    Combined circulating microRNA and peptide biomarkers for prognostication in heart failure.
    Cardiovasc Res. 2025 Apr 17:cvaf065. doi: 10.1093.
    >> Share

  27. JANSSEN-TELDERS C, Eringa EC, de Groot JR, de Man FS, et al
    The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction.
    Cardiovasc Res. 2025 Apr 16:cvaf056. doi: 10.1093.
    >> Share

    March 2025
  28. DAVIDSON SM, Andreadou I, Antoniades C, Bartunek J, et al
    Opportunities and challenges for the use of human samples in translational cardiovascular research: a scientific statement of the ESC Working Group on Cellular Biology of the Heart, the ESC Working Group on Cardiovascular Surgery, the ESC Council on B
    Cardiovasc Res. 2025 Mar 14:cvaf023. doi: 10.1093.
    >> Share

    February 2025
  29. TIMMER LT, den Hertog E, Versteeg D, Post H, et al
    Cardiomyocyte SORBS2 expression increases in heart failure and regulates integrin interactions and extracellular matrix composition.
    Cardiovasc Res. 2025 Feb 17:cvaf021. doi: 10.1093.
    >> Share

  30. SHANG R, Rodrigues B
    Cardioprotective effects of a 'twincretin' drug tirzepatide in heart failure following myocardial infarction.
    Cardiovasc Res. 2025 Feb 4:cvaf006. doi: 10.1093.
    >> Share

    January 2025
  31. STEFANSKA K, Sattar N
    Incretin-based weight loss therapies and heart failure with preserved ejection fraction: guideline impactful results, but mechanisms unclear.
    Cardiovasc Res. 2025 Jan 31:cvaf001. doi: 10.1093.
    >> Share

  32. SONI S, Skow RJ, Foulkes S, Haykowsky MJ, et al
    Therapeutic potential of ketone bodies on exercise intolerance in heart failure: looking beyond the heart.
    Cardiovasc Res. 2025 Jan 18:cvaf004. doi: 10.1093.
    >> Share

    December 2024
  33. SCHWARZ KG, Pereyra KV, Diaz-Jara E, Vicencio SC, et al
    Brainstem C1 neurons mediate heart failure decompensation and mortality during acute salt loading.
    Cardiovasc Res. 2024 Dec 30:cvae261. doi: 10.1093.
    >> Share

  34. FUKUMA N, Tokiwa H, Numata G, Ueda K, et al
    Endothelial oestrogen-myocardial cyclic guanosine monophosphate axis critically determines angiogenesis and cardiac performance during pressure overload.
    Cardiovasc Res. 2024;120:1884-1897.
    >> Share

    November 2024
  35. TUBBEN A, Markousis-Mavrogenis G, Meems LMG, van Essen BJ, et al
    Circulating ECM proteins decorin and alpha-L-iduronidase differentiate ATTRwt-CM from ATTRwt-negative HFpEF/HFmrEF.
    Cardiovasc Res. 2024;120:1727-1736.
    >> Share

  36. COROVIC A, Zhao X, Huang Y, Newland SR, et al
    Coronavirus disease 2019-related myocardial injury is associated with immune dysregulation in symptomatic patients with cardiac magnetic resonance imaging abnormalities.
    Cardiovasc Res. 2024;120:1752-1767.
    >> Share

  37. ALHASAN KA, King MA, Pattar BSB, Lewis IA, et al
    Anaplerotic filling in heart failure: a review of mechanism and potential therapeutics.
    Cardiovasc Res. 2024 Nov 21:cvae248. doi: 10.1093.
    >> Share

  38. MINISTRINI S, Camici GG
    Inflammation and heart failure: are we facing a "hedgehog's dilemma"?
    Cardiovasc Res. 2024 Nov 16:cvae246. doi: 10.1093.
    >> Share

  39. MONTUORO S, Gentile F, Giannoni A
    Neuroimmune cross-talk in heart failure.
    Cardiovasc Res. 2024 Nov 5:cvae236. doi: 10.1093.
    >> Share

    October 2024
  40. SUN Q, Karwi QG, Wong N, Lopaschuk GD, et al
    Advances in myocardial energy metabolism: metabolic remodeling in heart failure and beyond.
    Cardiovasc Res. 2024 Oct 25:cvae231. doi: 10.1093.
    >> Share

  41. FORTE M, Galli M, Sciarretta S
    Erbb3 and Hspa2, two novel predictors of heart failure in diabetic patients.
    Cardiovasc Res. 2024 Oct 25:cvae220. doi: 10.1093.
    >> Share

  42. NG YH, Koay YC, Marques FZ, Kaye DM, et al
    Leveraging metabolism for better outcomes in heart failure.
    Cardiovasc Res. 2024 Oct 1:cvae216. doi: 10.1093.
    >> Share

    September 2024
  43. HU W, Tu H, Wadman MC, Li YL, et al
    Renal denervation achieves its antiarrhythmic effect through attenuating macrophage activation and neuroinflammation in stellate ganglia in chronic heart failure.
    Cardiovasc Res. 2024 Sep 25:cvae196. doi: 10.1093.
    >> Share

  44. TAKAOKA M, Tadross JA, Al-Hadithi ABAK, Zhao X, et al
    GDF15 antagonism limits severe heart failure and prevents cardiac cachexia.
    Cardiovasc Res. 2024 Sep 23:cvae214. doi: 10.1093.
    >> Share

  45. YANG R, Ruan B, Wang R, Zhang X, et al
    Cardiomyocyte betaII spectrin plays a critical role in maintaining cardiac function by regulating mitochondrial respiratory function.
    Cardiovasc Res. 2024;120:1312-1326.
    >> Share

    August 2024
  46. CONNING-ROWLAND MS, Giannoudi M, Drozd M, Brown OI, et al
    The diabetic myocardial transcriptome reveals Erbb3 and Hspa2 as a novel biomarkers of incident heart failure.
    Cardiovasc Res. 2024 Aug 24:cvae181. doi: 10.1093.
    >> Share

    July 2024
  47. TRUM M, Riechel J, Schollmeier E, Lebek S, et al
    Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.
    Cardiovasc Res. 2024;120:999-1010.
    >> Share

    June 2024
  48. GRECO CM, Nisoli E
    The ketogenic diet is unable to improve cardiac function in ischemic heart failure: an unexpected result?
    Cardiovasc Res. 2024 Jun 6:cvae126. doi: 10.1093.
    >> Share

    May 2024
  49. FORTE M, Frati G, Sciarretta S
    Phosphodiesterase-mediated modulation of subcellular cAMP levels to reduce heart failure.
    Cardiovasc Res. 2024 May 24:cvae108. doi: 10.1093.
    >> Share

  50. PAVLAKI N, Froese A, Li W, De Jong KA, et al
    Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation.
    Cardiovasc Res. 2024 May 22:cvae094. doi: 10.1093.
    >> Share

  51. HO KL, Karwi Q, Wang F, Wagg C, et al
    The ketogenic diet does not improve cardiac function and blunts glucose oxidation in ischemic heart failure.
    Cardiovasc Res. 2024 May 1:cvae092. doi: 10.1093.
    >> Share

    April 2024
  52. KAHNERT K, Soattin L, Mills RW, Wilson C, et al
    Proteomics couples electrical remodelling to inflammation in a murine model of heart failure with sinus node dysfunction.
    Cardiovasc Res. 2024 Apr 25:cvae054. doi: 10.1093.
    >> Share

  53. KASS DA
    Benchmarking pre-clinical heart failure with preserved ejection fraction models: can we do better?
    Cardiovasc Res. 2024 Apr 4:cvae059. doi: 10.1093.
    >> Share

    March 2024
  54. RANGREZ AY, Frey N
    Reverse cardio-oncology: is heart failure-mediated gut dysbiosis the mechanistic driver of colorectal cancer progression?
    Cardiovasc Res. 2024 Mar 28:cvae051. doi: 10.1093.
    >> Share

  55. KESIDOU D, Beqqali A, Baker AH
    The dual effects of miR-222 in cardiac hypertrophy: bridging pathological and physiological paradigms.
    Cardiovasc Res. 2024;120:217-219.
    >> Share

    February 2024
  56. KIZER JR
    The elusive quest for causality in adiponectin's bimodal relationship with cardiovascular disease: Mendelian randomization meets Janus.
    Cardiovasc Res. 2024;120:3-5.
    >> Share

  57. ROLSKI F, Tkacz K, Weglarczyk K, Kwiatkowski G, et al
    TNF-alpha protects from exacerbated myocarditis and cardiac death by suppressing expansion of activated heart-reactive CD4+ T cells.
    Cardiovasc Res. 2024;120:82-94.
    >> Share

  58. DE WIT S, Geerlings L, Shi C, Dronkers J, et al
    Heart failure-induced microbial dysbiosis contributes to colonic tumour formation in mice.
    Cardiovasc Res. 2024 Feb 24:cvae038. doi: 10.1093.
    >> Share

  59. GOTTHARDT M, Lehnart SE
    SERCA2a microdomain cAMP changes in heart failure with preserved ejection fraction.
    Cardiovasc Res. 2024 Feb 9:cvae030. doi: 10.1093.
    >> Share

    January 2024
  60. SUN Q, Guven B, Wagg CS, de Oliveira AA, et al
    Mitochondrial fatty acid oxidation is the major source of cardiac ATP production in heart failure with preserved ejection fraction.
    Cardiovasc Res. 2024 Jan 9:cvae006. doi: 10.1093.
    >> Share

  61. ABOULEISA RRE, Tang XL, Ou Q, Salama AM, et al
    Gene therapy encoding cell cycle factors to treat chronic ischemic heart failure in rats.
    Cardiovasc Res. 2024 Jan 4:cvae002. doi: 10.1093.
    >> Share

    December 2023
  62. LAI P, Hille SS, Subramanian H, Weigman R, et al
    Remodelling of cAMP dynamics within the SERCA2a microdomain in heart failure with preserved ejection fraction caused by obesity and type 2 diabetes.
    Cardiovasc Res. 2023 Dec 14:cvad178. doi: 10.1093.
    >> Share

  63. LIU X, Li H, Hastings MH, Xiao C, et al
    miR-222 inhibits pathological cardiac hypertrophyand heart failure.
    Cardiovasc Res. 2023 Dec 12:cvad184. doi: 10.1093.
    >> Share

    November 2023
  64. KATTIH B, Boeckling F, Shumliakivska M, Tombor L, et al
    Single-nuclear transcriptome profiling identifies persistent fibroblast activation in hypertrophic and failing human hearts of patients with longstanding disease.
    Cardiovasc Res. 2023;119:2550-2562.
    >> Share

  65. CICCARELLI M, Pires IF, Bauersachs J, Bertrand L, et al
    Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial Function.
    Cardiovasc Res. 2023;119:2390-2404.
    >> Share

  66. CORRADI F, Masini G, Bucciarelli T, De Caterina R, et al
    Iron deficiency in myocardial ischaemia: molecular mechanisms and therapeutic perspectives.
    Cardiovasc Res. 2023;119:2405-2420.
    >> Share

  67. WU J, Subbaiah KCV, Hedaya O, Chen S, et al
    FAM210A regulates mitochondrial translation and maintains cardiac mitochondrial homeostasis.
    Cardiovasc Res. 2023;119:2441-2457.
    >> Share

  68. BECHMANN LE, Emanuelsson F, Nordestgaard BG, Benn M, et al
    Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose.
    Cardiovasc Res. 2023;119:2482-2493.
    >> Share

  69. ASHOUR D, Rebs S, Arampatzi P, Saliba AE, et al
    An interferon gamma response signature links myocardial aging and immunosenescence.
    Cardiovasc Res. 2023;119:2458-2468.
    >> Share

    October 2023
  70. NIELSEN MB, Colak Y, Benn M, Mason A, et al
    Plasma adiponectin levels and risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction: large scale observational and Mendelian randomization evidence.
    Cardiovasc Res. 2023 Oct 28:cvad162. doi: 10.1093.
    >> Share

  71. CUTHBERT JJ, Cleland JGF
    Should we resurrect acetazolamide as a diuretic for congestion due to heart failure?
    Cardiovasc Res. 2023 Oct 18:cvad148. doi: 10.1093.
    >> Share

    September 2023
  72. ZOCCALI C, Mallamaci F, Adamczak M, de Oliveira RB, et al
    Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association.
    Cardiovasc Res. 2023;119:2017-2032.
    >> Share

    August 2023
  73. CHEN X, Li X, Wu X, Ding Y, et al
    Integrin beta-like 1 mediates fibroblast-cardiomyocyte crosstalk to promote cardiac fibrosis and hypertrophy.
    Cardiovasc Res. 2023;119:1928-1941.
    >> Share

  74. VISTNES M, Erusappan PM, Sasi A, Norden ES, et al
    Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction.
    Cardiovasc Res. 2023;119:1915-1927.
    >> Share

    July 2023
  75. MARTIN TP, MacDonald EA, Bradley A, Watson H, et al
    RNA interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction.
    Cardiovasc Res. 2023 Jul 11:cvad107. doi: 10.1093.
    >> Share

  76. DA DALT L, Cabodevilla AG, Goldberg IJ, Norata GD, et al
    Cardiac lipid metabolism, mitochondrial function and heart failure.
    Cardiovasc Res. 2023 Jul 1:cvad100. doi: 10.1093.
    >> Share

    June 2023
  77. DAMMAN K, Testani J
    Cardiorenal interactions in heart failure - insights from recent therapeutic advances.
    Cardiovasc Res. 2023 Jun 26:cvad096. doi: 10.1093.
    >> Share

  78. SMART CD, Fehrenbach DJ, Wassenaar JW, Agrawal V, et al
    Immune profiling of murine cardiac leukocytes identifies Trem2 as a novel mediator of hypertensive heart failure.
    Cardiovasc Res. 2023 Jun 14:cvad093. doi: 10.1093.
    >> Share

  79. CHUNG B, Wang Y, Thiel M, Rostami F, et al
    Preemptive iron supplementation prevents myocardial iron deficiency and attenuates adverse remodelling after myocardial infarction.
    Cardiovasc Res. 2023 Jun 14:cvad092. doi: 10.1093.
    >> Share

  80. BASSUK SS, Manson JE
    Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence.
    Cardiovasc Res. 2023;119:1297-1309.
    >> Share

  81. KANY S, Al-Taie C, Roselli C, Pirruccello JP, et al
    Association of genetic risk and outcomes in patients with atrial fibrillation: interactions with early rhythm control in the EAST-AFNET4 trial.
    Cardiovasc Res. 2023 Jun 2:cvad027. doi: 10.1093.
    >> Share

    May 2023
  82. GROGAN A, Lucero EY, Jiang H, Rockman HA, et al
    Pathophysiology and pharmacology of G protein-coupled receptors in the heart.
    Cardiovasc Res. 2023;119:1117-1129.
    >> Share


  83. Corrigendum to: VEGF-B hypertrophy predisposes to transition from diastolic to systolic heart failure in hypertensive rats.
    Cardiovasc Res. 2023 May 15:cvad073. doi: 10.1093.
    >> Share

  84. DONG M, Chen D, Zhu Y, Yang S, et al
    Impaired regulation of MMP2/16-MLCK3 by miR-146a-5p increased susceptibility to myocardial ischaemic injury in aging mice.
    Cardiovasc Res. 2023;119:786-801.
    >> Share

  85. PHANG RJ, Ritchie RH, Hausenloy DJ, Lees JG, et al
    Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy.
    Cardiovasc Res. 2023;119:668-690.
    >> Share

    March 2023
  86. YANG X, Zhang M, Xie B, Peng Z, et al
    Myocardial brain-derived neurotrophic factor regulates cardiac bioenergetics through the transcription factor Yin Yang 1.
    Cardiovasc Res. 2023;119:571-586.
    >> Share

  87. SAMUELSSON AM, Bartolomaeus TUP, Anandakumar H, Thowsen I, et al
    VEGF-B hypertrophy predisposes to transition from diastolic to systolic heart failure in hypertensive rats.
    Cardiovasc Res. 2023 Mar 23:cvad040. doi: 10.1093.
    >> Share

  88. PARKSOOK WW, Williams GH
    Aldosterone and cardiovascular diseases.
    Cardiovasc Res. 2023;119:28-44.
    >> Share

  89. FAYYAZ AU, Sabbah MS, Dasari S, Griffiths LG, et al
    Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension.
    Cardiovasc Res. 2023;119:268-282.
    >> Share

  90. MARKOUSIS-MAVROGENIS G, Minich WB, Al-Mubarak AA, Anker SD, et al
    Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure.
    Cardiovasc Res. 2023 Mar 8:cvad042. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016